Modulation of normal and malignant plasma cells function by toll-like receptors
- PMID: 22202037
- DOI: 10.2741/e542
Modulation of normal and malignant plasma cells function by toll-like receptors
Abstract
Toll-like receptors (TLRs) are well known activators of immune responses, but their involvement in the plasma cell (PC) differentiation process remains mostly unknown. This review is focused on the expression and function of TLRs on normal PCs and their malignant counterpart, Multiple Myeloma cells. We report studies that suggest a role for TLR ligands as adjuvants of the humoral immune response through the survival of newly generated immature PCs. On the contrary, TLRs do not seem to be involved in the long-term maintenance of PCs in the bone marrow. Multiple Myeloma cells express a broad range of TLRs, and show heterogeneous responses to different ligands. These double-edged-sword effects are presented and discussed in the context of tumor progression, and as putative therapeutic targets.
Similar articles
-
Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.Br J Haematol. 2010 Sep;150(5):543-53. doi: 10.1111/j.1365-2141.2010.08284.x. Epub 2010 Jul 14. Br J Haematol. 2010. PMID: 20629663
-
Toll-like receptors: expression and involvement in multiple myeloma.Leuk Res. 2010 Dec;34(12):1545-50. doi: 10.1016/j.leukres.2010.06.002. Epub 2010 Jul 1. Leuk Res. 2010. PMID: 20594595 Review.
-
Toll-like receptors mediate proliferation and survival of multiple myeloma cells.Leukemia. 2006 Jun;20(6):1138-44. doi: 10.1038/sj.leu.2404225. Leukemia. 2006. PMID: 16617319
-
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.Blood. 2007 Jul 1;110(1):296-304. doi: 10.1182/blood-2006-10-051482. Epub 2007 Mar 15. Blood. 2007. PMID: 17363736
-
Toll-like receptors: New targets for multiple myeloma treatment?Biochem Pharmacol. 2022 May;199:114992. doi: 10.1016/j.bcp.2022.114992. Epub 2022 Mar 12. Biochem Pharmacol. 2022. PMID: 35292256 Review.
Cited by
-
p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy.Cancers (Basel). 2024 Jan 6;16(2):256. doi: 10.3390/cancers16020256. Cancers (Basel). 2024. PMID: 38254747 Free PMC article. Review.
-
Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches.Cancers (Basel). 2023 Feb 3;15(3):984. doi: 10.3390/cancers15030984. Cancers (Basel). 2023. PMID: 36765939 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical